JNJ - J&J to report Q2 result amid several macro factors that threaten to diminish near-term growth

• Johnson & Johnson ( NYSE: JNJ ) is scheduled to announce Q2 earnings results on Monday, July 18th, before market open.
• EPS Estimate is $2.55 (+2.8% Y/Y) and the consensus Revenue Estimate is $23.86B (+2.4% Y/Y).
• has beaten EPS estimates 100% of the time and has beaten revenue estimates 63% of the time.
• upward revision and 13 downward. Revenue estimates have seen 1 upward revision and 11 downward.
• J&J's stock fell on April 19, the day it reported Q1 results, where the company missed revenue estimates and lowered its adjusted EPS outlook for 2022.
• The New Brunswick, N.J.-based pharma giant's Q1 revenue rose +4.95% Y/Y to ~$23.43B but missed analysts estimates by ~$210M.
• Last quarter , the company also suspended its COVID-19 vaccine sales guidance, stating global supply surplus and demand uncertainty.
• In Q1, J&J lowered its adjusted EPS guidance to be between $10.15 and $10.35, compared to prior estimate of $10.40 - $10.60, provided in January. Consensus EPS Estimate for 2022 is $10.22.
• In May , Johnson & Johnson's stockholders voted against a proposal by certain shareholders to discontinue global sales of baby powder containing talc.
• The same month , the U.S. Food and Drug Administration has limited the authorized use of JNJ COVID-19 vaccine due to the risk of blood cot.
• The company also named two senior executives at its Consumer Health division as the CEO and CFO designates of its new consumer unit.
• JNJ notified Emergent BioSolutions ( EBS ) it is terminating its supply deal with the contract manufacturer, with the pharma giant accusing Emergent of breaching a contract, The Wall Street Journal reported in June.
• Also read - Top sticky stocks most immune to big earnings misses and beats.
• Recent earnings Analysis from our contributors: Johnson & Johnson: What To Know Before Upcoming Earnings .

For further details see: